Accro Bioscience Initiates Pivotal Phase IIb Trial for Novel Ulcerative Colitis Treatment AC-101

Cambridge, MA – [Current Date, e.g., October 26, 2023] – Accro Bioscience (Accro Bio), a clinical-stage biotechnology company at the forefront of developing innovative therapies for inflammatory and autoimmune diseases, today announced a significant milestone in its pipeline: the dosing of the first patient in its Phase IIb clinical trial for AC-101. This investigational selective receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor is being evaluated for its potential to treat moderate-to-severe ulcerative colitis (UC), a chronic and debilitating inflammatory bowel disease.

n

The initiation of this advanced clinical stage trial represents a crucial step forward for Accro Bioscience and offers a beacon of hope for the millions of patients worldwide grappling with the challenges of UC. AC-101, developed leveraging Accro Bio’s proprietary drug discovery platform focused on regulatory cell death and inflammation, targets a novel mechanism believed to underpin the persistent inflammation characteristic of UC.

n

The Phase IIb study is designed as a rigorous, placebo-controlled, double-blind, multi-centre trial, strategically planned to involve approximately 50 clinical sites across multiple geographies. This comprehensive approach aims to thoroughly assess the efficacy and safety profile of AC-101 across diverse patient populations. The trial will compare two distinct dose groups of AC-101 against a placebo arm, with the primary objective of determining the proportion of patients achieving clinical remission at week 12. Beyond this immediate goal, exploratory metrics will delve into the critical aspects of histologic remission and the maintenance of long-term remission, aiming to provide a holistic understanding of AC-101’s therapeutic potential.

n

Ulcerative colitis, a chronic inflammatory condition affecting the lining of the large intestine and rectum, imposes a substantial burden on patients, characterized by symptoms such as abdominal pain, bloody diarrhea, urgent bowel movements, fatigue, and weight loss. Despite advancements in therapeutic options, a significant unmet need persists for treatments that offer sustained remission, improve mucosal healing, and possess favorable safety profiles, particularly for those with moderate-to-severe disease who often fail to respond adequately to existing therapies or experience debilitating side effects. Accro Bioscience’s commitment to advancing AC-101 into Phase IIb underscores its potential to emerge as a vital new therapeutic option in this challenging landscape.

n

A Journey of Innovation: The Chronology of AC-101’s Development

n

The journey of AC-101 from concept to a pivotal Phase IIb trial is a testament to Accro Bioscience’s rigorous scientific approach and strategic development pathway. The company’s foundational work is rooted in a deep understanding of cellular biology, particularly the intricate mechanisms governing regulatory cell death and inflammation – processes that are often dysregulated in autoimmune and inflammatory diseases.

n

Early Discovery and Pre-clinical Validation (circa 2018-2020):nThe inception of AC-101 began with Accro Bioscience’s innovative drug discovery platform. Researchers at Accro Bio identified the receptor-interacting serine/threonine-protein kinase 2 (RIPK2) as a promising therapeutic target. RIPK2 plays a critical role as a mediator in the nucleotide-binding oligomerisation domain (NOD) signalling pathway, a key component of the innate immune system. Pre-clinical studies meticulously elucidated that dysregulation or disruption of the NOD/RIPK2 signalling pathway is intimately associated with the pathogenesis of various inflammatory and autoimmune conditions, including inflammatory bowel disease (IBD). This scientific rationale provided a strong basis for developing a selective RIPK2 inhibitor. Through extensive in-vitro and in-vivo studies, AC-101 demonstrated its ability to modulate this pathway effectively, showing promising anti-inflammatory effects and a favorable preliminary safety profile in animal models, thereby paving the way for human clinical trials.

n

Phase I Studies: Establishing Safety and Pharmacokinetics (2021-2022):nFollowing successful pre-clinical development, AC-101 transitioned into Phase I clinical trials. These studies, crucial for assessing the drug’s safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles in humans, were conducted in healthy volunteer cohorts across Australia and China. The multi-regional approach was designed to gather comprehensive data from diverse populations. Accro Bioscience reported a "favourable safety and pharmacokinetic/pharmacodynamic profile" from these initial human studies. While specific data points were not detailed in the announcement, this positive outcome indicated that AC-101 was well-tolerated across the tested dose ranges and exhibited predictable absorption, distribution, metabolism, and excretion characteristics, along with evidence of engaging its intended biological target. These findings were instrumental in building confidence for further clinical development.

n

Phase Ib Proof-of-Concept Study: First Look at Efficacy in UC Patients (2022-2023):nBuilding upon the robust safety data from Phase I, Accro Bioscience advanced AC-101 into a Phase Ib proof-of-concept study. This crucial trial specifically enrolled Chinese patients diagnosed with moderate-to-severe ulcerative colitis. The primary objective of this study was to obtain initial signals of clinical efficacy and further assess the safety profile of AC-101 within the target patient population. While a comprehensive data release is pending, the completion of this study is a significant achievement. The company has announced that the detailed safety and efficacy findings from this Phase Ib study are slated for presentation at the prestigious United European Gastroenterology (UEG) Week 2026. This upcoming presentation is highly anticipated by the gastroenterology community, as it will offer the first public glimpse into AC-101’s potential therapeutic benefits in UC patients. The positive trajectory from Phase I to the completion of Phase Ib provided the necessary data and confidence to progress directly into the larger, more definitive Phase IIb trial.

n

Transition to Phase IIb: A Pivotal Step Towards Registration (Current):nThe initiation of the Phase IIb trial marks the culmination of years of dedicated research and development. It signifies Accro Bioscience’s strong belief in AC-101’s potential to address the significant unmet needs in moderate-to-severe UC. This phase is designed to confirm the preliminary efficacy signals observed in Phase Ib, establish optimal dosing regimens, and gather more extensive safety data from a larger patient cohort, thereby laying the groundwork for potential Phase III pivotal studies and eventual regulatory submission.

n

Supporting Data: Unpacking Ulcerative Colitis and AC-101’s Mechanism

n

Ulcerative colitis is a chronic inflammatory condition of the colon and rectum, characterized by a relapsing and remitting course. It is one of two major forms of inflammatory bowel disease (IBD), affecting millions globally. The exact cause of UC remains unknown, but it is believed to involve a complex interplay of genetic predisposition, environmental factors, and an aberrant immune response that leads to sustained inflammation of the gastrointestinal tract. Symptoms vary but commonly include persistent diarrhea often mixed with blood, abdominal pain and cramping, urgency to defecate, tenesmus, fatigue, and weight loss. The disease significantly impairs patients’ quality of life, leading to frequent hospitalizations, increased risk of colorectal cancer, and, in severe cases, the need for surgical removal of the colon.

n

The Current Treatment Landscape and Unmet Needs:nCurrent therapeutic strategies for moderate-to-severe UC typically involve a step-up approach, starting with aminosalicylates, followed by corticosteroids for acute flares, and then progressing to immunomodulators (e.g., azathioprine, methotrexate) and biologics (e.g., TNF inhibitors like infliximab and adalimumab, integrin inhibitors like vedolizumab, IL-12/23 inhibitors like ustekinumab). More recently, small molecule inhibitors like JAK inhibitors (e.g., tofacitinib, upadacitinib) have been approved. While these therapies have revolutionized UC management, significant challenges persist:

n

n
• Primary Non-response: A substantial proportion of patients do not respond to initial therapy.

n

• Secondary Loss of Response: Many patients who initially respond eventually lose efficacy over time.

n

• Side Effects: Immunosuppressive therapies carry risks of serious infections, malignancies, and other adverse events.

n

• Convenience: Many biologics require intravenous infusions or subcutaneous injections, which can be burdensome.

n

• Mucosal Healing: Achieving deep and sustained mucosal healing, a key predictor of long-term remission and reduced colorectal cancer risk, remains an elusive goal for many.nThe search for novel therapeutic targets with improved efficacy, safety, and convenience profiles is therefore paramount.

n

n

AC-101: A Novel Approach Targeting RIPK2:nAC-101’s mechanism of action offers a fresh perspective in this complex disease. It is a selective inhibitor of receptor-interacting serine/threonine-protein kinase 2 (RIPK2). To understand its potential, one must delve into the role of RIPK2 within the innate immune system.

n

The NOD-like receptor (NLR) pathway, particularly the NOD1 and NOD2 receptors, are crucial intracellular sensors that detect pathogen-associated molecular patterns (PAMPs) from bacteria, especially those residing in the gut. Upon sensing these patterns, NOD1 and NOD2 activate RIPK2. Activated RIPK2 then initiates a signaling cascade that ultimately leads to the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPKs). This activation results in the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and chemokines, which are essential for mounting an immune response and clearing infections.

n

However, in chronic inflammatory conditions like UC, this finely tuned pathway can become dysregulated, leading to excessive and persistent inflammation. Genetic mutations in NOD2, for instance, are strongly associated with Crohn’s disease (another IBD), highlighting the pathway’s critical role in gut immunity. In UC, while direct NOD2 mutations are less common, the general hyper-responsiveness of innate immune pathways, including NOD/RIPK2, is thought to contribute to the chronic inflammatory state.

By selectively inhibiting RIPK2, AC-101 aims to dampen this exaggerated inflammatory signaling pathway. The selectivity is crucial, as it suggests the potential for a more targeted intervention with fewer off-target effects compared to broader immunosuppressants. The hypothesized therapeutic benefits of AC-101 in UC include:

• Reduction of Pro-inflammatory Cytokines: By blocking RIPK2, AC-101 can suppress the downstream production of inflammatory mediators that drive UC pathogenesis.
• Modulation of Immune Cell Activation: It may help to restore a more balanced immune response in the gut, reducing the recruitment and activation of inflammatory cells.
• Potential for Mucosal Healing: By reducing chronic inflammation, AC-101 could promote the healing of the damaged intestinal lining, which is essential for sustained remission.
• Novelty: As a RIPK2 inhibitor, AC-101 represents a distinct mechanism of action from existing biologics and small molecules, potentially offering an effective option for patients who do not respond to current therapies.

Phase IIb Trial Design: A Closer Look:
The Phase IIb trial is meticulously designed to provide robust data. Its key features include:

• Placebo-controlled and Double-blind: These features minimize bias by ensuring neither patients nor clinicians know who is receiving the active drug versus placebo. This is the gold standard for clinical trials.
• Multi-centre: Conducting the trial across approximately 50 sites ensures a diverse patient population and enhances the generalizability of the results. It also facilitates faster patient recruitment.
• Patient Population: Focusing on moderate-to-severe UC patients is strategic, as this group has the highest unmet medical need and is most likely to benefit from novel therapies.
• Dose Groups: Comparing two active dose groups of AC-101 against placebo will help identify the optimal therapeutic dose, balancing efficacy with safety.
• Primary Endpoint: Clinical Remission at Week 12: Clinical remission is typically defined by a significant reduction in UC symptoms, often assessed using validated scoring systems like the Mayo Score (which considers stool frequency, rectal bleeding, endoscopic findings, and physician global assessment). A 12-week timeframe is standard for assessing initial induction of remission in UC trials.
• Exploratory Metrics: Histologic Remission and Long-term Remission Maintenance: These endpoints are increasingly recognized as critical for comprehensive UC management. Histologic remission (mucosal healing) refers to the absence of active inflammation at a microscopic level, correlating with improved long-term outcomes. Assessing long-term remission maintenance beyond 12 weeks is vital to determine the drug’s durability and its potential to alter the disease course. The trial design suggests a potential extension phase or careful follow-up to evaluate these crucial long-term benefits.

Official Responses and Company Vision

Accro Bioscience’s leadership has consistently articulated a clear vision for addressing chronic inflammatory and autoimmune diseases through targeted molecular mechanisms. The dosing of the first patient in the AC-101 Phase IIb trial has been met with significant enthusiasm within the company.

"This is a momentous occasion for Accro Bioscience and, more importantly, for patients suffering from moderate-to-severe ulcerative colitis," stated Dr. [Fictional CEO Name], Chief Executive Officer of Accro Bioscience. "The initiation of our Phase IIb trial for AC-101 represents a critical advancement in our mission to bring transformative therapies to those with high unmet medical needs. Our rigorous pre-clinical and early clinical data, particularly the favorable safety and efficacy signals from our Phase Ib study, have given us immense confidence in AC-101’s potential. We believe that by selectively inhibiting RIPK2, we can offer a novel and effective treatment option that addresses the underlying inflammatory drivers of UC."

Dr. [Fictional CMO Name], Chief Medical Officer at Accro Bioscience, further elaborated on the trial’s significance: "The design of our Phase IIb study is robust and comprehensive, aiming to gather definitive data on AC-101’s ability to induce clinical and, crucially, histologic remission. We are particularly keen to explore its potential for long-term remission maintenance, which is a paramount goal for both patients and clinicians. The chronic nature of UC demands therapies that not only alleviate acute symptoms but also fundamentally alter the disease course, and we are optimistic that AC-101 could achieve this by modulating the critical NOD/RIPK2 pathway."

The company’s commitment extends beyond AC-101. Accro Bioscience’s proprietary drug discovery platform, which focuses on regulatory cell death, is designed to identify and develop other pipeline compounds for various inflammatory and autoimmune diseases. "Our platform is built on the premise that targeting the fundamental mechanisms of cell death and inflammation can unlock novel therapeutic strategies," added Dr. [Fictional Head of R&D Name], Head of Research and Development. "AC-101 is a prime example of this philosophy in action, and its progress validates our scientific approach and the potential of our broader pipeline."

Independent experts in the field of gastroenterology also recognize the potential impact of such novel approaches. Professor [Fictional KOL Name], a leading gastroenterologist and IBD specialist at [Fictional University Hospital], commented, "The current therapeutic arsenal for ulcerative colitis, while improved, still leaves many patients struggling. The concept of targeting the RIPK2 pathway represents an exciting new frontier. If AC-101 can demonstrate strong efficacy with a favorable safety profile in this Phase IIb trial, it could significantly expand our options, especially for those who are refractory to existing treatments. The focus on histologic remission and long-term maintenance is particularly encouraging, as these are increasingly recognized as essential for truly impactful therapies."

Implications: Future Outlook and Market Impact

The successful progression of AC-101 into Phase IIb holds significant implications for patients, Accro Bioscience, and the broader ulcerative colitis treatment landscape.

Potential Impact on the UC Treatment Paradigm:
Should AC-101 demonstrate positive results in its Phase IIb trial, it could fundamentally alter the treatment paradigm for moderate-to-severe UC. Its novel mechanism of action, targeting RIPK2, offers a distinct advantage by potentially addressing a pathway not directly modulated by current classes of drugs. This could provide an effective option for patients who have failed or are intolerant to existing biologics or JAK inhibitors, thereby filling a critical gap in care. As a small molecule inhibitor, it is highly likely that AC-101 is an orally administered therapy, which would offer a significant convenience advantage over injectable biologics, potentially improving patient adherence and overall quality of life. The focus on histologic remission and long-term maintenance also suggests a potential for AC-101 to offer more profound and durable disease control, moving beyond symptom management to true mucosal healing.

Accro Bioscience’s Strategic Position:
For Accro Bioscience, a successful Phase IIb trial would be transformative. It would:

• Validate the Pipeline: A positive outcome would validate the company’s proprietary drug discovery platform and its ability to identify and advance promising drug candidates, strengthening confidence in its other pipeline assets.
• Attract Investment and Partnerships: Robust Phase IIb data is a critical de-risking event that can attract significant investment, strategic partnerships, or even acquisition interest from larger pharmaceutical companies looking to expand their IBD portfolios. This would provide the necessary capital and infrastructure for subsequent Phase III trials and commercialization.
• Leadership in Novel Mechanisms: Establishing AC-101 as a leading RIPK2 inhibitor would position Accro Bioscience as a pioneer in this novel therapeutic area, enhancing its reputation in the competitive biotechnology sector.
• Pathway to Market: Positive Phase IIb data would provide the foundation for designing pivotal Phase III trials, which are essential for gaining regulatory approvals from agencies like the FDA and EMA.

Market Potential and Competition:
The global market for inflammatory bowel disease treatments is substantial and continues to grow, driven by increasing prevalence, diagnostic improvements, and the demand for more effective therapies. Analysts project the IBD market to reach tens of billions of dollars in the coming years. Within this crowded market, a novel oral therapy with a differentiated mechanism of action and strong efficacy/safety profile like AC-101 could capture a significant share, especially in the challenging moderate-to-severe segment. While the competitive landscape is robust with established biologics and emerging small molecules, the unmet needs ensure there is ample room for truly innovative and effective new entrants.

Challenges and Risks:
Despite the optimism, the path to drug approval is fraught with challenges. Clinical trials, particularly in complex diseases like UC, carry inherent risks. Phase IIb trials can be demanding in terms of patient recruitment, data collection, and statistical power. Furthermore, the regulatory landscape is stringent, requiring compelling evidence of both efficacy and safety. Accro Bioscience will need to navigate these hurdles effectively, ensuring meticulous trial execution and transparent data reporting. The competitive environment also means that other companies are simultaneously developing new therapies, underscoring the importance of AC-101’s differentiation and clinical success.

In conclusion, the initiation of Accro Bioscience’s Phase IIb trial for AC-101 represents a beacon of progress in the ongoing fight against ulcerative colitis. With its novel mechanism targeting the RIPK2 pathway, AC-101 holds the promise of a new, effective, and potentially more convenient treatment option for patients who desperately need better solutions. The global medical community and patients alike will be keenly awaiting the results of this pivotal study, hopeful that it will usher in a new era of relief and improved quality of life for those living with this challenging chronic condition.